ACRS
Aclaris Therapeutics, Inc.
$4.36
0.00%
$600.6M
No data for this timeframe.
Vol
Market Cap$600.6M
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (88%)
Inst. Holders8 funds
Inst. Value$36.5M
Inst. Activity2 buys / 1 sells
Insider Activity0B / 1S
Insider Net $-$1.4M
SEC Reports5
Press Releases4
Recent Activity
Jun 8, 2026
short_volume
Short Volume: ACRS — 60.3% short (0.4M / 0.6M)
Short: 389,072 | Exempt: 0 | TRF Vol: 645,178 | Short Ratio: 60.3% | Off-exchange volume (dark pool
Jun 5, 2026
Insider
MILANO VINCENT sold 11,580 shares
Director @ $0.00 ($0.00)
Jun 5, 2026
Insider
GOWEN MAXINE sold 11,580 shares
Director @ $0.00 ($0.00)
Jun 5, 2026
Insider
Molineaux Christopher P. sold 11,580 shares
Director @ $0.00 ($0.00)
Apr 28, 2026
SEC
Aclaris reported positive full Phase 1a SAD/MAD results for ATI-052, an anti-TSLP/IL-4R bispecific antibody, showing a f
8-K — Impact 8/10
Apr 28, 2026
Press
Aclaris reported positive full Phase 1a results for ATI-052, an anti-TSLP/IL-4Rα bispecific antibody, showing a 45-day h
Impact 7/10
Apr 23, 2026
SEC
Aclaris Therapeutics, Inc. is holding its 2026 Annual Meeting of Stockholders. The meeting will be held virtually on Jun
DEFA14A — Impact 2/10
Mar 11, 2026
SEC
Analysis based on filing metadata only — document content was unavailable. The 8-K filing includes Item 7.01 (Regulation
8-K — Impact 3/10
Price Targets
$10.00
+132.6% upside
Strong Buy
Current $4.30
Low $4.00
Median $10.00
High $16.00
10 analysts
$4.00
$16.00
Analyst Ratings
8Strong Buy
7Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 2, 2026 | LifeSci Capital | INITIATE | Outperform |
| May 5, 2026 | Piper Sandler | MAINTAIN | Overweight → Overweight |
| May 5, 2026 | Guggenheim | INITIATE | Buy |
| Apr 29, 2026 | Wedbush | MAINTAIN | Outperform → Outperform |
| Apr 16, 2026 | Oppenheimer | INITIATE | Outperform |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.16 ▼ -2.1% | $-0.18 — $-0.12 | -23% YoY | 8 |
| Next Q | $-0.17 ▼ -15.0% | $-0.23 — $-0.11 | -44% YoY | 8 |
| Current FY | $-0.66 ▼ -2.3% | $-0.79 — $-0.49 | -24% YoY | 8 |
| Next FY | $-0.83 ▼ -9.7% | $-1.65 — $-0.51 | -27% YoY | 9 |
Latest Reports
BULLISH
8-K
8/10
Aclaris reported positive full Phase 1a SAD/MAD results for ATI-052, an anti-TSLP/IL-4R bispecific antibody, showing a f
Apr 28, 2026
BULLISH
Press
7/10
Aclaris reported positive full Phase 1a results for ATI-052, an anti-TSLP/IL-4Rα bispecific antibody, showing a 45-day h
Apr 28, 2026
NEUTRAL
DEFA14A
2/10
Aclaris Therapeutics, Inc. is holding its 2026 Annual Meeting of Stockholders. The meeting will be held virtually on Jun
Apr 23, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $19.6M | ADD |
| MORGAN STANLEY | $10.3M | ADD |
| RENAISSANCE TECHNOLOGIES LLC | $3.4M | TRIM |
| TWO SIGMA INVESTMENTS, LP | $1.7M | ADD |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $856.7K | DOUBLED |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 5, 2026 | MILANO VINCENT | M | $0.00 |
| Jun 5, 2026 | GOWEN MAXINE | M | $0.00 |
| Jun 5, 2026 | Molineaux Christopher | M | $0.00 |
| Jun 5, 2026 | GOWEN MAXINE | M | $0.00 |
| Jun 5, 2026 | Mehra Anand | M | $0.00 |
8 institutional holders with $36.5M total value (12,116,411 shares) as of 2025-Q4. Top holders: VANGUARD, MORGAN, RENAISSANCE. Net buying activity: 2 institutions added/increased vs 1 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 6,502,080 | $19.6M | 53.7% | ADD +34.0% |
| 2 | MORGAN STANLEY | 3,415,390 | $10.3M | 28.2% | ADD +46.6% |
| 3 | RENAISSANCE TECHNOLOGIES LLC | 1,125,331 | $3.4M | 9.3% | TRIM -30.5% |
| 4 | TWO SIGMA INVESTMENTS, LP | 574,213 | $1.7M | 4.7% | ADD +56.0% |
| 5 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 284,604 | $856.7K | 2.3% | DOUBLED +689.9% |
| 6 | WELLS FARGO & COMPANY/MN | 104,465 | $314.4K | 0.9% | ADD +53.5% |
| 7 | BANK OF AMERICA CORP /DE/ | 64,521 | $194.2K | 0.5% | TRIM -56.7% |
| 8 | FMR LLC | 45,807 | $137.9K | 0.4% | NEAR_EXIT -90.9% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 1,619,731 | 1,125,331 | -30.5% | $3.4M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | ADD | 368,107 | 574,213 | +56.0% | $1.7M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 68,039 | 104,465 | +53.5% | $314.4K | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 749,660 | 368,107 | -50.9% | $699.4K | 2025-Q3 |
| UBS Group AG | TRIM | 153,172 | 105,138 | -31.4% | $199.8K | 2025-Q3 |
| FMR LLC | NEAR_EXIT | 442,247 | 40,350 | -90.9% | $76.7K | 2025-Q3 |
| VANGUARD GROUP INC | ADD | 4,970,254 | 6,662,063 | +34.0% | $9.5M | 2025-Q2 |
| MORGAN STANLEY | ADD | 2,415,584 | 3,540,192 | +46.6% | $5.0M | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 951,394 | 1,464,778 | +54.0% | $2.1M | 2025-Q2 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | DOUBLED | 33,079 | 261,298 | +689.9% | $371.0K | 2025-Q2 |
| UBS Group AG | DOUBLED | 73,992 | 153,172 | +107.0% | $217.5K | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | TRIM | 167,669 | 72,595 | -56.7% | $103.1K | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | DOUBLED | 4,590 | 62,840 | +1269.1% | $89.2K | 2025-Q2 |
| MORGAN STANLEY | DOUBLED | 1,071,784 | 2,415,584 | +125.4% | $3.7M | 2025-Q1 |
| CITADEL ADVISORS LLC | DOUBLED | 109,047 | 1,159,181 | +963.0% | $1.8M | 2025-Q1 |
| MORGAN STANLEY | DOUBLED | 480,773 | 1,071,784 | +122.9% | $2.7M | 2024-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 1,370,700 | 850,519 | -38.0% | $2.1M | 2024-Q4 |
| CITADEL ADVISORS LLC | TRIM | 369,067 | 109,047 | -70.5% | $270.4K | 2024-Q4 |
| UBS Group AG | DOUBLED | 31,852 | 69,463 | +118.1% | $172.3K | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 33,079 | — | $82.0K | 2024-Q4 |
| MORGAN STANLEY | DOUBLED | 186,343 | 480,773 | +158.0% | $552.9K | 2024-Q3 |
13 unique insiders with 1 transactions. Net insider value: -$1.4M ($0.00 bought, $1.4M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 5, 2026 | MILANO VINCENT | Director | M | 11,580 | $0.00 | $0.00 |
| Jun 5, 2026 | GOWEN MAXINE | Director | M | 11,580 | $0.00 | $0.00 |
| Jun 5, 2026 | Molineaux Christopher P. | Director | M | 11,580 | $0.00 | $0.00 |
| Jun 5, 2026 | GOWEN MAXINE | Director | M | 11,580 | $0.00 | $0.00 |
| Jun 5, 2026 | Mehra Anand | Director | M | 11,580 | $0.00 | $0.00 |
| Jun 5, 2026 | Mehra Anand | Director | M | 11,580 | $0.00 | $0.00 |
| Jun 5, 2026 | Humphries William D. | Director | M | 11,580 | $0.00 | $0.00 |
| Jun 5, 2026 | SCHIFF ANDREW N | Director | M | 11,580 | $0.00 | $0.00 |
| Jun 5, 2026 | Humphries William D. | Director | M | 11,580 | $0.00 | $0.00 |
| Jun 5, 2026 | Molineaux Christopher P. | Director | M | 11,580 | $0.00 | $0.00 |
| Jun 5, 2026 | SCHIFF ANDREW N | Director | M | 11,580 | $0.00 | $0.00 |
| Jun 5, 2026 | MILANO VINCENT | Director | M | 11,580 | $0.00 | $0.00 |
| Jun 4, 2026 | Mehra Anand | Director | A | 10,987 | $0.00 | $0.00 |
| Jun 4, 2026 | SCHIFF ANDREW N | Director | A | 10,987 | $0.00 | $0.00 |
| Jun 4, 2026 | Humphries William D. | Director | A | 42,350 | $0.00 | $0.00 |
| Jun 4, 2026 | MILANO VINCENT | Director | A | 42,350 | $0.00 | $0.00 |
| Jun 4, 2026 | Molineaux Christopher P. | Director | A | 10,987 | $0.00 | $0.00 |
| Jun 4, 2026 | GOWEN MAXINE | Director | A | 10,987 | $0.00 | $0.00 |
| Jun 4, 2026 | GOWEN MAXINE | Director | A | 42,350 | $0.00 | $0.00 |
| Jun 4, 2026 | Humphries William D. | Director | A | 10,987 | $0.00 | $0.00 |
| Jun 4, 2026 | Mehra Anand | Director | A | 42,350 | $0.00 | $0.00 |
| Jun 4, 2026 | SCHIFF ANDREW N | Director | A | 42,350 | $0.00 | $0.00 |
| Jun 4, 2026 | Molineaux Christopher P. | Director | A | 42,350 | $0.00 | $0.00 |
| Jun 4, 2026 | MILANO VINCENT | Director | A | 10,987 | $0.00 | $0.00 |
| May 1, 2026 | Hall Jesse Wayne | Chief Medical Officer | M | 36,375 | $0.00 | $0.00 |
| May 1, 2026 | Hall Jesse Wayne | Chief Medical Officer | F | 9,330 | $4.41 | $41.1K |
| May 1, 2026 | Hall Jesse Wayne | Chief Medical Officer | M | 36,375 | $0.00 | $0.00 |
| Apr 23, 2026 | Leonard Braden Michael | 10%+ Owner | SELL | 300,000 | $4.53 | $1.4M |
| Mar 1, 2026 | Balthaser Kevin | Chief Financial Officer | M | 2,375 | $0.00 | $0.00 |
| Mar 1, 2026 | Balthaser Kevin | Chief Financial Officer | M | 2,375 | $0.00 | $0.00 |
| Feb 3, 2026 | Walker Neal | CEO | M | 63,475 | $0.00 | $0.00 |
| Feb 3, 2026 | Walker Neal | CEO | F | 18,611 | $3.47 | $64.6K |
| Feb 3, 2026 | Walker Neal | CEO | M | 63,475 | $0.00 | $0.00 |
| Feb 3, 2026 | Balthaser Kevin | Chief Financial Officer | M | 22,025 | $0.00 | $0.00 |
| Feb 3, 2026 | Balthaser Kevin | Chief Financial Officer | F | 6,449 | $3.47 | $22.4K |
| Feb 3, 2026 | Balthaser Kevin | Chief Financial Officer | M | 22,025 | $0.00 | $0.00 |
| Feb 3, 2026 | Davis Hugh M. | President and COO | M | 18,675 | $0.00 | $0.00 |
| Feb 3, 2026 | Davis Hugh M. | President and COO | M | 18,675 | $0.00 | $0.00 |
| Feb 3, 2026 | Loerop James | Chief Business Officer | M | 20,875 | $0.00 | $0.00 |
| Feb 3, 2026 | Loerop James | Chief Business Officer | F | 5,937 | $3.47 | $20.6K |
| Feb 3, 2026 | Loerop James | Chief Business Officer | M | 20,875 | $0.00 | $0.00 |
| Feb 2, 2026 | Loerop James | Chief Business Officer | A | 97,700 | $0.00 | $0.00 |
| Feb 2, 2026 | Loerop James | Chief Business Officer | A | 341,900 | $0.00 | $0.00 |
| Feb 2, 2026 | Davis Hugh M. | President and COO | A | 96,100 | $0.00 | $0.00 |
| Feb 2, 2026 | Davis Hugh M. | President and COO | A | 336,300 | $0.00 | $0.00 |
| Feb 2, 2026 | Walker Neal | CEO | A | 274,800 | $0.00 | $0.00 |
| Feb 2, 2026 | Walker Neal | CEO | A | 961,700 | $0.00 | $0.00 |
| Feb 2, 2026 | Kolbeck Roland Wilhelm | Chief Scientific Officer | A | 95,700 | $0.00 | $0.00 |
| Feb 2, 2026 | Kolbeck Roland Wilhelm | Chief Scientific Officer | A | 334,900 | $0.00 | $0.00 |
| Feb 2, 2026 | Hall Jesse Wayne | Chief Medical Officer | A | 98,100 | $0.00 | $0.00 |
5 SEC filing reports analyzed. Sentiment: 2 bullish, 0 bearish, 1 mixed, 2 neutral. Avg impact: 5.0/10.
BULLISH
8-K
8/10
Aclaris reported positive full Phase 1a SAD/MAD results for ATI-052, an anti-TSLP/IL-4R bispecific a
Apr 28, 2026
NEUTRAL
DEFA14A
2/10
Aclaris Therapeutics, Inc. is holding its 2026 Annual Meeting of Stockholders. The meeting will be h
Apr 23, 2026
NEUTRAL
8-K
3/10
Analysis based on filing metadata only — document content was unavailable. The 8-K filing includes I
Mar 11, 2026
BULLISH
INST-CLUSTER
6/10
Three major institutional investors — Morgan Stanley, UBS, and Schwab — significantly increased thei
Feb 28, 2026
MIXED
8-K
6/10
Aclaris Therapeutics reported financial results for Q4 and full year 2025, showing a significant red
Feb 26, 2026
BULLISH
7/10
Aclaris reported positive full Phase 1a results for ATI-052, an anti-TSLP/IL-4Rα bispecific antibody
Apr 28, 2026
BULLISH
8/10
Aclaris Therapeutics released additional Phase 2a trial data for its investigational oral drug ATI-2
Mar 27, 2026
NEUTRAL
3/10
Aclaris Therapeutics announced the presentation of new results from the open-label Phase 2a trial of
Mar 20, 2026
NEUTRAL
5/10
Aclaris Therapeutics announced completion of patient enrollment in its Phase 2 trial of bosakitug (A
Mar 18, 2026
Current analyst consensus: Strong Buy (88% buy). Based on 17 analysts: 8 strong buy, 7 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$10.00 mean target
+132.6% upside
Strong Buy (1.27)
$4.00 Low
$16.00 High
| Metric | Value |
|---|---|
| Current Price | $4.30 |
| Target Low | $4.00 |
| Target Mean | $10.00 |
| Target Median | $10.00 |
| Target High | $16.00 |
| # Analysts | 10 |
| Recommendation | Strong Buy (1.27) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.16 | $-0.18 | $-0.12 | -23.1% | -2.1% | 1↑ 1↓ | $0.0B | -22.2% | 8 |
| Next Q 2026-09-30 |
$-0.17 | $-0.23 | $-0.11 | -43.8% | -15.0% | 1↑ 2↓ | $0.0B | -59.4% | 8 |
| Current FY 2026-12-31 |
$-0.66 | $-0.79 | $-0.49 | -23.6% | -2.3% | 2↑ 2↓ | $0.0B | -27.0% | 8 |
| Next FY 2027-12-31 |
$-0.83 | $-1.65 | $-0.51 | -26.5% | -9.7% | 3↑ 1↓ | $0.0B | -6.2% | 9 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.160 | |
| 7d ago | $-0.159 | -0.001 |
| 30d ago | $-0.157 | -0.003 |
| 60d ago | $-0.154 | -0.006 |
| 90d ago | $-0.156 | -0.004 |
6 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 3 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 2, 2026 | LifeSci Capital | INITIATE | — | Outperform |
| May 5, 2026 | Piper Sandler | MAINTAIN | Overweight | Overweight |
| May 5, 2026 | Guggenheim | INITIATE | — | Buy |
| Apr 29, 2026 | Wedbush | MAINTAIN | Outperform | Outperform |
| Apr 16, 2026 | Oppenheimer | INITIATE | — | Outperform |
| Mar 31, 2026 | Wedbush | REITERATE | Outperform | Outperform |
| Mar 19, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Jan 28, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Jan 21, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 8 | 7 | 2 | 0 | 0 | 88% | |
| May 1, 2026 | 7 | 7 | 2 | 0 | 0 | 88% | |
| Apr 1, 2026 | 6 | 7 | 2 | 0 | 0 | 87% | |
| Mar 1, 2026 | 5 | 7 | 2 | 0 | 0 | 86% | |
| Feb 1, 2026 | 5 | 7 | 2 | 0 | 0 | 86% | |
| Jan 1, 2026 | 5 | 6 | 2 | 0 | 0 | 85% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 8, 2026
short_volume
Short Volume: ACRS — 60.3% short (0.4M / 0.6M)
Short: 389,072 | Exempt: 0 | TRF Vol: 645,178 | Short Ratio: 60.3% | Off-exchange volume (dark pool + OTC)
May 28, 2026
other
Aclaris Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
Aclaris Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
May 19, 2026
Clinical Trial
ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis
Phase Phase 2 — ACTIVE_NOT_RECRUITING
May 19, 2026
clinical_trial_readout
T-90d Trial Readout: ATI-045 (Phase 2)
Trial: ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis
Sponsor: Aclaris Therapeutics, Inc.
Phase: Phase 2 | Status: ACTIV
May 13, 2026
clinical_trial_readout
T-90d Trial Readout: ATI-045 (Phase 2)
Trial: ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis
Sponsor: Aclaris Therapeutics, Inc.
Phase: Phase 2 | Status: ACTIV
May 12, 2026
earnings_calendar
ACRS Q1 2026 Earnings Scheduled — 2026-05-12
May 8, 2026
other
Aclaris Therapeutics to Participate in the 2026 Bank of America Healthcare Conference
Aclaris Therapeutics to Participate in the 2026 Bank of America Healthcare Conference
May 7, 2026
earnings
Aclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update
Aclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update
May 4, 2026
clinical_trial_readout
T-90d Trial Readout: ATI-045 (Phase 2)
Trial: ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis
Sponsor: Aclaris Therapeutics, Inc.
Phase: Phase 2 | Status: ACTIV
May 3, 2026
clinical_trial_readout
T-90d Trial Readout: ATI-045 (Phase 2)
Trial: ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis
Sponsor: Aclaris Therapeutics, Inc.
Phase: Phase 2 | Status: ACTIV
Apr 28, 2026
fda
Aclaris Therapeutics Announces Positive Full Top Line First-in-Human Results from Phase 1a Healthy Volunteer Clinical Trial of ATI-052, a Novel Potential First-in-Class Anti-TSLP/IL-4Rα Bispecific Antibody, and Announces Lichen Planus as Lead Indication for ATI-2138, an Oral ITK/JAK3 Inhibitor
Aclaris Therapeutics Provides Update on Key Biologic and Oral Inhibitor Clinical Programs
Apr 27, 2026
fda
Aclaris Therapeutics to Provide Clinical Update on Key Biologic and Oral Inhibitor Programs on April 28, 2026
Aclaris Therapeutics to Provide Clinical Update on Key Biologic and Oral Inhibitor Programs
on April 28, 2026
Apr 24, 2026
short_volume
Short Volume: ACRS — 63.0% short (0.4M / 0.7M)
Short: 417,163 | Exempt: 150 | TRF Vol: 662,344 | Short Ratio: 63.0% | Off-exchange volume (dark pool + OTC)
Apr 22, 2026
short_volume
Short Volume: ACRS — 92.6% short (1.4M / 1.5M)
Short: 1,391,020 | Exempt: 500 | TRF Vol: 1,502,400 | Short Ratio: 92.6% | Off-exchange volume (dark pool + OTC)
Apr 8, 2026
other
Aclaris Therapeutics to Participate in the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference
Aclaris Therapeutics to Participate in the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference
Mar 31, 2026
short_volume
Short Volume: ACRS — 79.8% short (1.0M / 1.3M)
Short: 1,008,003 | Exempt: 0 | TRF Vol: 1,263,755 | Short Ratio: 79.8% | Off-exchange volume (dark pool + OTC)